Health Care

Media Hit | Health Care

Pay for Delay

Dr. Michael Wilkes from the University of California, Davis school of Medicine talks about pay-for-delay on his KCRW show "Second Opinion" 

Media Hit | Health Care

Consumers are paying more money for certain drugs

The California Public Interest Research Group  released the report on  a practice critics call "Pay for delay."   That's when brand name drug companies pay off generic manufacturers to delay putting generic versions on the market.  As a result, consumers end up paying a lot more. The study found in some cases hundreds of dollars more were spent on meds used to treat cancer,  depression and heart disease. 

Media Hit | Health Care

Pharmaceutical companies pay to delay generics

The report, from the California Public Interest Research Group and Community Catalyst, a nonprofit advocate for affordable health care, said pay-for-delay deals enable companies to continue to sell their brand-name drugs at high prices well after their original patents have expired.

Media Hit | Health Care

Drug Makers Stall Generics With “Pay For Delay” Says CALPIRG

The California Public Interest Research Group or CALPIRG has released details on what it says is a practice that leads to prescription drug price inflation. CALPIRG calls it “pay for delay.” CALPIRG says the practice of keeping generics off the market makes consumers pay more for medications that treat conditions like cancer and high cholesterol.

Media Hit | Health Care

CALPIRG study claims drug companies hold back generic meds

SACRAMENTO, Calif. (KCRA) —A study by a public interest group found Californians have overpaid for medications because brand-made drugs were delayed from reaching pharmacies.

Read more: http://www.kcra.com/news/calpirg-study-claims-drug-companies-hold-back-generic-meds/-/11797728/20945964/-/uh9rdr/-/index.html#ixzz2YrSJnikK

News Release | CALPIRG | Health Care

Twenty Top Generic Drugs Delayed By Industry Payoffs

The report, “Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers” reveals that these drugs were subject to an industry practice called “pay for delay,” in which brand name pharmaceutical companies pay off generic drug manufacturers to keep lower cost equivalents off the market, forcing consumers to pay higher brand-name drug prices.

Report | CALPIRG | Health Care

Top Twenty Pay-For-Delay Drugs

Californians with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 blockbuster drugs, according to a report released today by California Public Interest Research Group (CALPIRG) and Community Catalyst.

 

 

The report, “Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers,” reveals that these drugs were subject to an industry practice called “pay for delay,” in which brand name pharmaceutical companies pay off generic drug manufacturers to keep lower cost equivalents off the market, forcing consumers to pay higher brand-name drug prices.

Media Hit | Health Care

High court rules 'pay-for-delay' drug deals can face antitrust suits

"While we're disappointed the court did not take the next step and outlaw this anti-competitive practice, we expect Congressto now give this issue the attention it deserves and end these deals once and for all," said Austin Price, field director for the California Public Interest Research Group.

News Release | CALPIRG Education Fund | Health Care

Covered California Announces New Plans and Rates for 2014

“Today’s announcement is the exciting next step in ensuring that Californians can access affordable and reliable heath care coverage,” said Jon Fox.

Big Pharma’s anti-competitive practice costs consumers $3.5 billion a year. The 1984 Hatch-Waxman Act was originally intended to increase the availability of generic drugs by allowing generic manufacturers to challenge the patents of name-brand drugs. What emerged in the aftermath was a practice where patent-holding pharmaceutical companies simply paid generic manufacturers not to challenge their patents, thus delaying the release of generic drugs for years. 

Pages

Subscribe to RSS - Health Care

DEFEND THE CFPB

Tell your representative to oppose the “Financial CHOICE Act,” which would gut Wall Street reforms and destroy the Consumer Financial Protection Bureau as we know it.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code

Support Us

Your donation supports CALPIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.